MAG
CSTL icon

Millrace Asset Group’s Castle Biosciences CSTL Stock Holding History

Millrace Asset Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,506
Closed -$381K – 77
2024
Q2 		$381K Sell
17,506
-32,267
-65% -$719K 0.37% 70
2024
Q1 		$1.1M Sell
49,773
-29,141
-37% -$634K 1.11% 52
2023
Q4 		$1.7M Buy
78,914
+1,599
+2% +$28.1K 1.69% 23
2023
Q3 		$1.31M Buy
+77,315
New +$1.35M 1.61% 30
2022
Q4 		– Sell
-63,345
Closed -$1.65M – 53
2022
Q3 		$1.65M Buy
+63,345
New +$1.78M 2.09% 17

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millrace Asset Group's CSTL Position: Q3 2024 in Review

Millrace Asset Group sold out of Castle Biosciences (CSTL) in Q3 2024, closing a stake of 17,506 shares — an estimated $381K sold.

Millrace Asset Group first reported a position in CSTL in Q3 2022 and held it in 5 quarters. The position peaked at $1.7M in Q4 2023. 185 funds tracked by Wall St. Rank hold CSTL as of Q3 2024.

  • Millrace Asset Group reported no remaining Castle Biosciences position as of Q3 2024 after selling out during the quarter.
  • Millrace Asset Group sold 17,506 Castle Biosciences shares in Q3 2024, an estimated $381K.
  • Millrace Asset Group first reported a position in Castle Biosciences in Q3 2022 and held it in 5 quarters.
  • Millrace Asset Group's Castle Biosciences position peaked at $1.7M in Q4 2023.
  • 185 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2024.

Based on Millrace Asset Group's 13F filing for Q3 2024, filed 13 Nov 2024.